Overall verdict
Neutral
6.3/10
1-year performance
-1.35%
Score breakdown
Down 1.3% over 1 year, 75% of the 52-week range.
Strongest: Profitability 9.2/10. Weakest: Valuation 1.1/10.
14 analysts, target +0.0% vs the price.
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits.
It also provides commercial reference laboratory diagnostic and consulting services to veterinarians ; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting ; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water ; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments ;
UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests ; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry ; human medical diagnostic products and services ; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station.
It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Sector
Health Care
Industry
Health Care Equipment and Supplies
Primary listing
Nasdaq
United States
CEO
Michael Erickson
Founded
1983
Employees
11 000
Revenue / employee
391 246 USD
Next earnings
February 5, 2027 (estimated)
Institutional holders
- GEODE CAPITAL MANAGEMENT, LLC3.33%
- Bank of New York Mellon Corp1.19%
- FMR LLC1.17%
- Rest of the register94.31%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
769.98 USD
52-week low
500.61 USD
1-year performance
-1.35%
Declining
Year-to-date performance
3.89%
Declining
Drawdown
-8.72%
Mild pullback
Position in the 52-week range
75% of range
Against the world ETF
Over 26 years, from December 2000 to October 2026, the share did better than the world ETF once risk is accounted for.
$10,000 placed at the end of December 2000 are worth today
| IDEXX Laboratories | $1,002,200 |
| World ETF | $65,117 |
| S&P 500 | $91,204 |
| Risk-free placement | $15,894 |
The risk
- Shaking:the share moves 2.0 times as much as the world ETF.
- Worst fall:-54Â % between August 2021 and October 2022. $10,000 placed at the top fell to $4,600. The world ETF, at worst: -53Â %. Back to its high in 37 months.
IDEXX Laboratories earned 15 times as much as the world ETF since 2000
Value of $10,000 placed at the end of December 2000, dividends reinvested, in dollars
- IDEXX Laboratories: $1,002,200
- World ETF: $65,117
- S&P 500: $91,204
- Risk-free placement: $15,894
Based on past performance. This is not a recommendation.
Range: 320.02 USD - 349.79 USD (comparables only)
The price implies growth of 14.90% per year; the company grows at 14.28%.
Gross margin 62.8%, net margin 25.4%, ROIC 54.9%, ROE 68.9%.
Net margin
25.36%
Exceptional
Sector 9.11%|S&P 13.40%
Gross margin
62.78%
Fair
Return on equity (ROE)
68.93%
Exceptional
Sector 7.42%|S&P 17.06%
Return on invested capital (ROIC)
54.87%
Exceptional
Free cash flow margin (FCF)
27.89%
Exceptional
Profit-to-cash conversion (FCF conversion)
1.10x
High
Margin stability
4.0 pts
Steady
Revenue to net income
Growth
7.3/10Revenue up 9.9% over 1 year, 9.7% a year over 5, EPS 14.3% a year over 5.
Revenue (trailing 12 months)
4.7Md USD
Revenue growth (1y)
9.86%
Solid
Revenue growth (3y)
27.81%
Solid
EPS growth (1y)
17.86%
Hyper-growth
EPS CAGR (5y)
14.28%
Strong
EPS revisions (3 months)
1.10%
Revised up
Valuation
1.1/10P/E 47.4x, forward P/E 46.7x, EV/EBITDA 33.4x, PEG 3.32. The multiple sits in the 64th percentile of its own 5-year history.
P/E (TTM)
47.4x
Expensive
Sector 29.2x|S&P 23.6x
Forward P/E
46.7x
Very expensive
EV / EBITDA
33.4x
Very expensive
Sector 14.2x|S&P 15.5x
PEG
3.32
Very expensive
Sector 1.25|S&P 0.91
Fair value (reverse DCF)
334.90 USD
Deeply overvalued
P/E vs its own 5-year history
among the 36% highest valuations
Pricier than usual
Market cap
55.4Md USD
Financial strength
8.6/10Cash covers 20.3% of the debt, net debt/EBITDA 0.5x.
Net debt / EBITDA
0.5x
Solid
Gearing (net debt / equity)
41.48%
Solid
Cash
198M USD
Cash / market cap
0.36%
Stretched
Cash / total debt
20.30%
Tight
Interest coverage
43.5x
Very solid
Net debt
775M USD
Equity
1.9Md USD
Closed daily candles, 2 years
Last close on November 10, 2026: 696.64 USD
- MM20602.22
- MM50552.57
- MM200572.12
- RSI 1471.5
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-1.80%
200-day average slope, 3 months
-7.48%
50-day average slope, 1 month
+2.57%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
5.20 % per day
Volatility change
+164.14%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 15.04 (10) | 15.00 (11) | 4 753 (13) | 1 696 (10) | 1 195 (9) |
| 2027 | 16.81 (11) | 16.88 (13) | 5 174 (13) | 1 870 (10) | 1 322 (10) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 10, 2026.
Same sub-industry: 187 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | SYK | 6.5 | 6.1 | 121Md USD | 34.0x | 13.8 % | 7.6 % | 9.7 % | 1.7x | 3.8 % | -10.5 % | ||
| 2 | IDXX | 6.3 | 5.7 | 55.4Md USD | 47.4x | 25.4 % | 9.9 % | 54.9 % | 0.5x | 2.3 % | -1.3 % | ||
| 3 | ISRG | 6.2 | 5.5 | 156Md USD | 54.4x | 25.5 % | 21.7 % | 18.0 % | -1.6x | 2.3 % | -21.8 % | ||
| 4 | MDT | 6.2 | 6.7 | 130Md USD | 25.0x | 13.9 % | 13.7 % | 7.0 % | 2.0x | 4.7 % | 9.3 % | ||
| 5 | ABT | 6.0 | 5.2 | 189Md USD | 40.3x | 9.8 % | 14.5 % | 6.6 % | 0.5x | 3.6 % | -13.7 % | ||
| 6 | EW | 5.9 | 5.1 | 60.8Md USD | 61.6x | 14.9 % | 10.5 % | 8.9 % | -2.0x | 2.3 % | 25.3 % | ||
| 7 | BSX | 5.6 | 6.4 | 65.4Md USD | 19.1x | 16.6 % | 1.4 % | 9.8 % | 1.8x | 5.1 % | -55.5 % | ||
| 8 | BDX | 5.5 | 5.3 | 58.4Md USD | 51.8x | 7.4 % | -10.5 % | 3.6 % | 2.9x | 4.6 % | 49.4 % | ||
| 9 | SHL | 5.3 | 5.3 | 53.1Md USD | 22.0x | 9.4 % | 7.3 % | 7.3 % | 2.8x | 4.3 % | 0.0 % |
